New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
09:02 EDTBAXBaxter to acquire Chatham Therapeutics
Baxter International and Chatham Therapeutics announced that Baxter has agreed to acquire all of Chatham’s outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia. Under the terms of the agreement, Baxter will make an initial payment of $70M to acquire all of the outstanding membership interests of Chatham. Baxter may make additional payments in the future based on specified development, regulatory and commercial milestones. Baxter will continue the ongoing Phase I/II open-label clinical trial to assess the safety and optimal dosing schedule of BAX 335, an investigational FIX gene therapy treatment for hemophilia B. The BNP technology provides a mechanism for the patient's own liver to begin producing FIX following a single dose of the genetically engineered treatment. The design of the vector allows for more targeted delivery of the FIX therapeutic “cargo” into the natural site of FIX synthesis. This may permit effective therapy with low quantities of the vector. The Phase I/II clinical trial is proceeding as expected and aims to enroll up to 16 hemophilia B patients. Following the acquisition, Chatham will maintain its licensing and development relationship with Asklepios BioPharmaceutical on the development of novel hemophilia therapeutic gene therapy candidates using the Biological Nano Particle platform. AskBio is involved with the development of its proprietary BNPTM gene-delivery platform technology for therapeutics targeting diseases in the heart, CNS, muscle, ocular and liver tissues.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
09:15 EDTBAXBaxter says 'feels good' about guidance
Subscribe for More Information
08:56 EDTBAXBaxter: Guidance contemplates possible headwinds related to cyclo competition
Subscribe for More Information
07:05 EDTBAXBaxter sees Q3 EPS before special items $1.28-$1.32, consensus $1.32
The company said, "For Q3, the company expects sales growth of approximately 12%-13%, excluding the impact of foreign currency. TheQ3 earnings guidance excludes approximately 7c per diluted share of projected intangible asset amortization expense."
07:04 EDTBAXBaxter narrows FY14 adjusted EPS view to $5.10-$5.20, consensus $5.15
Subscribe for More Information
07:02 EDTBAXBaxter reports Q2 adjusted EPS $1.26, consensus $1.22
Reports Q2 revenue $4.26B, consensus $4.12B.
07:01 EDTBAXBaxter confirms FY14 outlook
Subscribe for More Information
July 16, 2014
15:27 EDTBAXNotable companies reporting before tomorrow's open
Subscribe for More Information
July 10, 2014
08:17 EDTBAXBaxter volatility flat into Q2 and outlook
Subscribe for More Information
July 9, 2014
09:02 EDTBAXBaxter acquires AesRx, specific terms not disclosed
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use